GSK Receives Authorization for RSV Vaccine From European Commission
By Christian Moess Laursen
GSK said Wednesday that it has received authorization for its respiratory syncytial virus vaccine Arexvy from the European Commission, the executive body of the EU.
The London-listed pharmaceutical giant said the vaccine will help protect adults 60 years of age or older in 30 European countries from RSV disease for the first time. It is the first time an RSV vaccine for older adults have been granted European marketing authorization, it said.
The first launches are planned ahead of the 2023-24 RSV season which typically starts in the autumn, GSK said.
In Europe, RSV leads to over 270,000 hospitalizations and around 20,000 in-hospital deaths in adults aged 60 or older.
The authorisation is based on phase 3 efficacy data in older adults, GSK said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
June 07, 2023 02:39 ET (06:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett
-
DuPont Split Gives Investors Better Choices
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy